Pfizer Has 41% Of Arthritis Market Post-Vioxx
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and FDA have agreed to "black box" for Bextra skin reactions and will address safety in post-op patients "separately" in new labeling. Pfizer plans NDA for parecoxib by the end of the year.
You may also be interested in...
Smoking, Headaches And Allergies: Rx Pipeline Drugs May Impact OTCs
Rx products which could have implications for OTC markets include Schering-Merck’s Claritin/Singulair combination and new Schering Clarinex formulations. Pfizer’s nicotine replacement therapy varenicline is in Phase III; Relpax and Celebrex gain market share in migraine, arthritis markets, respectively.
Smoking, Headaches And Allergies: Rx Pipeline Drugs May Impact OTCs
Rx products which could have implications for OTC markets include Schering-Merck’s Claritin/Singulair combination and new Schering Clarinex formulations. Pfizer’s nicotine replacement therapy varenicline is in Phase III; Relpax and Celebrex gain market share in migraine, arthritis markets, respectively.
Bextra Contraindicated In CABG Surgery Patients
Labeling change to add "black box" for serious skin reactions incorporates post-surgery safety data, including results from two coronary artery bypass graft trials that show increased cardiovascular risk with Pfizer's COX-2 inhibitor.